ID

31845

Descrizione

Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis; ODM derived from: https://clinicaltrials.gov/show/NCT00665925

collegamento

https://clinicaltrials.gov/show/NCT00665925

Keywords

versioni (1)
  1. 02/10/18 02/10/18 -
Titolare del copyright

See clinicaltrials.gov

Caricato su

2 ottobre 2018

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Rheumatoid Arthritis NCT00665925

Inglese

Eligibility Rheumatoid Arthritis NCT00665925

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients must give written informed consent by signing an irb/ec-approved informed consent form (icf) prior to admission to this study.
Descrizione

Informed Consent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021430
males and females, 18 years of age or older, with active ra for at least 6 months prior to day 1 dosing.
Descrizione

Age | Rheumatoid Arthritis Duration

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2,1]
C0003873
UMLS CUI [2,2]
C0449238
patients must have been receiving weekly methotrexate doses (7.5-25 mg/week) for a minimum of 3 months prior to day 1 dosing and must be receiving a stable mtx dose, with no change in route, for the previous 6 weeks prior to day 1 dosing.
Descrizione

Methotrexate Dose Stable U/week

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0025677
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0205360
UMLS CUI [1,4]
C0560588
`patients must be receiving a folic or folinic acid supplementation at a stable dose for at least 6 weeks prior to day 1 dosing.
Descrizione

Folic acid supplementation Dose Stable | Folinic acid Supplementation Dose Stable

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0556110
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0205360
UMLS CUI [2,1]
C0023413
UMLS CUI [2,2]
C0242297
UMLS CUI [2,3]
C0178602
UMLS CUI [2,4]
C0205360
females of childbearing potential must be fully informed of the potential for r788 to adversely affect the fetus and, if sexually active, must agree to use a well established method of birth control during the study (oral contraceptive, mechanical barrier, long acting hormonal agent). these patients must not be lactating and must have a negative urine pregnancy test at the time of randomization and at each laboratory determination.
Descrizione

Childbearing Potential Informed R788 compound | Childbearing Potential Sexually active Contraceptive methods | Contraceptives, Oral | Contraception, Barrier | Hormonal contraception Active Long-term | Childbearing Potential Breast Feeding Absent | Childbearing Potential Urine pregnancy test negative

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C1522154
UMLS CUI [1,3]
C2002836
UMLS CUI [2,1]
C3831118
UMLS CUI [2,2]
C0241028
UMLS CUI [2,3]
C0700589
UMLS CUI [3]
C0009905
UMLS CUI [4]
C0004764
UMLS CUI [5,1]
C2985296
UMLS CUI [5,2]
C0205177
UMLS CUI [5,3]
C0443252
UMLS CUI [6,1]
C3831118
UMLS CUI [6,2]
C0006147
UMLS CUI [6,3]
C0332197
UMLS CUI [7,1]
C3831118
UMLS CUI [7,2]
C0430057
the patient must otherwise be in good health as determined by the investigator on the basis of medical history, physical examination, and laboratory screening tests during the screening period. see exclusion criteria for specific exclusions.
Descrizione

General health good Medical History | General health good Physical Examination | General health good Laboratory test

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1277245
UMLS CUI [1,2]
C0262926
UMLS CUI [2,1]
C1277245
UMLS CUI [2,2]
C0031809
UMLS CUI [3,1]
C1277245
UMLS CUI [3,2]
C0022885
in the investigator's opinion, the patient has the ability to understand the nature of the study and any hazards of participation, and to communicate satisfactorily with the investigator and to participate in, and to comply with, the requirements of the entire protocol.
Descrizione

Comprehension Study Protocol | Able to communicate Research Personnel | Protocol Compliance

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0162340
UMLS CUI [1,2]
C2348563
UMLS CUI [2,1]
C2364293
UMLS CUI [2,2]
C0035173
UMLS CUI [3]
C0525058
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
the patient has a history of, or a concurrent, clinically significant illness, medical condition (other than arthritis) or laboratory abnormality that, in the investigator's opinion, could affect the conduct of the study. specifically, excluded are patients with the following:
Descrizione

Illness Affecting Completion of clinical trial | Medical condition Affecting Completion of clinical trial | Laboratory test result abnormal Affecting Completion of clinical trial

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0221423
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C2732579
UMLS CUI [2,1]
C3843040
UMLS CUI [2,2]
C0392760
UMLS CUI [2,3]
C2732579
UMLS CUI [3,1]
C0438215
UMLS CUI [3,2]
C0392760
UMLS CUI [3,3]
C2732579
1. uncontrolled or poorly controlled hypertension;
Descrizione

Uncontrolled hypertension | Poor hypertension control

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1868885
UMLS CUI [2]
C0421190
2. other autoimmune disease (psoriatic arthritis, lupus, mixed connective disorder) or arthritis syndromes (gout, lyme disease, reiter's syndrome);
Descrizione

Autoimmune Disease | Arthritis, Psoriatic | Lupus Erythematosus | Mixed Connective Tissue Disease | Arthritis Syndrome | Gout | Lyme Disease | Reiter Syndrome

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0004364
UMLS CUI [2]
C0003872
UMLS CUI [3]
C0409974
UMLS CUI [4]
C0026272
UMLS CUI [5,1]
C0003864
UMLS CUI [5,2]
C0039082
UMLS CUI [6]
C0018099
UMLS CUI [7]
C0024198
UMLS CUI [8]
C0035012
3. recent (within past 2 months prior to day 1 dosing) serious surgery or infectious disease;
Descrizione

Operative Surgical Procedures Serious | Communicable Disease Serious

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0543467
UMLS CUI [1,2]
C0205404
UMLS CUI [2,1]
C0009450
UMLS CUI [2,2]
C0205404
4. recent history (past 5 years prior to day 1 dosing) of, or treatment for, a malignancy other than nonmelanomatous skin cancer, or any history of lymphoma;
Descrizione

Malignant Neoplasms | Cancer treatment | Exception Skin carcinoma | Lymphoma

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0006826
UMLS CUI [2]
C0920425
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0699893
UMLS CUI [4]
C0024299
5. hepatitis b ;
Descrizione

Hepatitis B

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0019163
6. hepatitis c ;
Descrizione

Hepatitis C

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0019196
7. interstitial pneumonitis or active pulmonary infection on chest x-ray;
Descrizione

Interstitial Pneumonia Chest X-ray | Infectious disease of lung Chest X-ray

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0206061
UMLS CUI [1,2]
C0039985
UMLS CUI [2,1]
C0876973
UMLS CUI [2,2]
C0039985
8. tuberculosis (tb): the tb skin test should be negative.
Descrizione

Tuberculosis | Tuberculosis Skin Test Negative

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0041296
UMLS CUI [2,1]
C3282342
UMLS CUI [2,2]
C1513916
9. known laboratory abnormalities.
Descrizione

Laboratory test result abnormal

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0438215
the patient has a history of substance abuse, drug addiction or alcoholism. patients may consume up to 4 units of alcohol per week; however, alcohol should be avoided in the 72 hours prior to lab assessments. patients who cannot reliably comply with this should be excluded. a unit of alcohol is defined as the following: beer=12 oz or 355 ml; wine = 5 oz or 148 ml; sweet dessert wine=3 oz or 89 ml; 80 proof distilled spirits= 1.5 oz or 44 ml.
Descrizione

Substance Use Disorders | Drug Dependence | Alcoholic Intoxication, Chronic | Alcohol consumption U/week | Beer Alcohol units | Wine Alcohol units | Dessert wine Alcohol units | Distilled spirits Alcohol units

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0038586
UMLS CUI [2]
C1510472
UMLS CUI [3]
C0001973
UMLS CUI [4,1]
C0001948
UMLS CUI [4,2]
C0560588
UMLS CUI [5,1]
C0004922
UMLS CUI [5,2]
C0556604
UMLS CUI [6,1]
C0043188
UMLS CUI [6,2]
C0556604
UMLS CUI [7,1]
C0454276
UMLS CUI [7,2]
C0556604
UMLS CUI [8,1]
C0301611
UMLS CUI [8,2]
C0556604
the patient has been treated previously treated with r788 under a different protocol.
Descrizione

Study Subject Participation Status | R788 compound

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C2002836
Ritorna all'inizio della pagina

Similar models

Eligibility Rheumatoid Arthritis NCT00665925

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Informed Consent
Item
patients must give written informed consent by signing an irb/ec-approved informed consent form (icf) prior to admission to this study.
boolean
C0021430 (UMLS CUI [1])
Age | Rheumatoid Arthritis Duration
Item
males and females, 18 years of age or older, with active ra for at least 6 months prior to day 1 dosing.
boolean
C0001779 (UMLS CUI [1])
C0003873 (UMLS CUI [2,1])
C0449238 (UMLS CUI [2,2])
Methotrexate Dose Stable U/week
Item
patients must have been receiving weekly methotrexate doses (7.5-25 mg/week) for a minimum of 3 months prior to day 1 dosing and must be receiving a stable mtx dose, with no change in route, for the previous 6 weeks prior to day 1 dosing.
boolean
C0025677 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,3])
C0560588 (UMLS CUI [1,4])
Folic acid supplementation Dose Stable | Folinic acid Supplementation Dose Stable
Item
`patients must be receiving a folic or folinic acid supplementation at a stable dose for at least 6 weeks prior to day 1 dosing.
boolean
C0556110 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,3])
C0023413 (UMLS CUI [2,1])
C0242297 (UMLS CUI [2,2])
C0178602 (UMLS CUI [2,3])
C0205360 (UMLS CUI [2,4])
Childbearing Potential Informed R788 compound | Childbearing Potential Sexually active Contraceptive methods | Contraceptives, Oral | Contraception, Barrier | Hormonal contraception Active Long-term | Childbearing Potential Breast Feeding Absent | Childbearing Potential Urine pregnancy test negative
Item
females of childbearing potential must be fully informed of the potential for r788 to adversely affect the fetus and, if sexually active, must agree to use a well established method of birth control during the study (oral contraceptive, mechanical barrier, long acting hormonal agent). these patients must not be lactating and must have a negative urine pregnancy test at the time of randomization and at each laboratory determination.
boolean
C3831118 (UMLS CUI [1,1])
C1522154 (UMLS CUI [1,2])
C2002836 (UMLS CUI [1,3])
C3831118 (UMLS CUI [2,1])
C0241028 (UMLS CUI [2,2])
C0700589 (UMLS CUI [2,3])
C0009905 (UMLS CUI [3])
C0004764 (UMLS CUI [4])
C2985296 (UMLS CUI [5,1])
C0205177 (UMLS CUI [5,2])
C0443252 (UMLS CUI [5,3])
C3831118 (UMLS CUI [6,1])
C0006147 (UMLS CUI [6,2])
C0332197 (UMLS CUI [6,3])
C3831118 (UMLS CUI [7,1])
C0430057 (UMLS CUI [7,2])
General health good Medical History | General health good Physical Examination | General health good Laboratory test
Item
the patient must otherwise be in good health as determined by the investigator on the basis of medical history, physical examination, and laboratory screening tests during the screening period. see exclusion criteria for specific exclusions.
boolean
C1277245 (UMLS CUI [1,1])
C0262926 (UMLS CUI [1,2])
C1277245 (UMLS CUI [2,1])
C0031809 (UMLS CUI [2,2])
C1277245 (UMLS CUI [3,1])
C0022885 (UMLS CUI [3,2])
Comprehension Study Protocol | Able to communicate Research Personnel | Protocol Compliance
Item
in the investigator's opinion, the patient has the ability to understand the nature of the study and any hazards of participation, and to communicate satisfactorily with the investigator and to participate in, and to comply with, the requirements of the entire protocol.
boolean
C0162340 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])
C2364293 (UMLS CUI [2,1])
C0035173 (UMLS CUI [2,2])
C0525058 (UMLS CUI [3])
Item Group
C0680251 (UMLS CUI)
Illness Affecting Completion of clinical trial | Medical condition Affecting Completion of clinical trial | Laboratory test result abnormal Affecting Completion of clinical trial
Item
the patient has a history of, or a concurrent, clinically significant illness, medical condition (other than arthritis) or laboratory abnormality that, in the investigator's opinion, could affect the conduct of the study. specifically, excluded are patients with the following:
boolean
C0221423 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C2732579 (UMLS CUI [1,3])
C3843040 (UMLS CUI [2,1])
C0392760 (UMLS CUI [2,2])
C2732579 (UMLS CUI [2,3])
C0438215 (UMLS CUI [3,1])
C0392760 (UMLS CUI [3,2])
C2732579 (UMLS CUI [3,3])
Uncontrolled hypertension | Poor hypertension control
Item
1. uncontrolled or poorly controlled hypertension;
boolean
C1868885 (UMLS CUI [1])
C0421190 (UMLS CUI [2])
Autoimmune Disease | Arthritis, Psoriatic | Lupus Erythematosus | Mixed Connective Tissue Disease | Arthritis Syndrome | Gout | Lyme Disease | Reiter Syndrome
Item
2. other autoimmune disease (psoriatic arthritis, lupus, mixed connective disorder) or arthritis syndromes (gout, lyme disease, reiter's syndrome);
boolean
C0004364 (UMLS CUI [1])
C0003872 (UMLS CUI [2])
C0409974 (UMLS CUI [3])
C0026272 (UMLS CUI [4])
C0003864 (UMLS CUI [5,1])
C0039082 (UMLS CUI [5,2])
C0018099 (UMLS CUI [6])
C0024198 (UMLS CUI [7])
C0035012 (UMLS CUI [8])
Operative Surgical Procedures Serious | Communicable Disease Serious
Item
3. recent (within past 2 months prior to day 1 dosing) serious surgery or infectious disease;
boolean
C0543467 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0009450 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
Malignant Neoplasms | Cancer treatment | Exception Skin carcinoma | Lymphoma
Item
4. recent history (past 5 years prior to day 1 dosing) of, or treatment for, a malignancy other than nonmelanomatous skin cancer, or any history of lymphoma;
boolean
C0006826 (UMLS CUI [1])
C0920425 (UMLS CUI [2])
C1705847 (UMLS CUI [3,1])
C0699893 (UMLS CUI [3,2])
C0024299 (UMLS CUI [4])
Hepatitis B
Item
5. hepatitis b ;
boolean
C0019163 (UMLS CUI [1])
Hepatitis C
Item
6. hepatitis c ;
boolean
C0019196 (UMLS CUI [1])
Interstitial Pneumonia Chest X-ray | Infectious disease of lung Chest X-ray
Item
7. interstitial pneumonitis or active pulmonary infection on chest x-ray;
boolean
C0206061 (UMLS CUI [1,1])
C0039985 (UMLS CUI [1,2])
C0876973 (UMLS CUI [2,1])
C0039985 (UMLS CUI [2,2])
Tuberculosis | Tuberculosis Skin Test Negative
Item
8. tuberculosis (tb): the tb skin test should be negative.
boolean
C0041296 (UMLS CUI [1])
C3282342 (UMLS CUI [2,1])
C1513916 (UMLS CUI [2,2])
Laboratory test result abnormal
Item
9. known laboratory abnormalities.
boolean
C0438215 (UMLS CUI [1])
Substance Use Disorders | Drug Dependence | Alcoholic Intoxication, Chronic | Alcohol consumption U/week | Beer Alcohol units | Wine Alcohol units | Dessert wine Alcohol units | Distilled spirits Alcohol units
Item
the patient has a history of substance abuse, drug addiction or alcoholism. patients may consume up to 4 units of alcohol per week; however, alcohol should be avoided in the 72 hours prior to lab assessments. patients who cannot reliably comply with this should be excluded. a unit of alcohol is defined as the following: beer=12 oz or 355 ml; wine = 5 oz or 148 ml; sweet dessert wine=3 oz or 89 ml; 80 proof distilled spirits= 1.5 oz or 44 ml.
boolean
C0038586 (UMLS CUI [1])
C1510472 (UMLS CUI [2])
C0001973 (UMLS CUI [3])
C0001948 (UMLS CUI [4,1])
C0560588 (UMLS CUI [4,2])
C0004922 (UMLS CUI [5,1])
C0556604 (UMLS CUI [5,2])
C0043188 (UMLS CUI [6,1])
C0556604 (UMLS CUI [6,2])
C0454276 (UMLS CUI [7,1])
C0556604 (UMLS CUI [7,2])
C0301611 (UMLS CUI [8,1])
C0556604 (UMLS CUI [8,2])
Study Subject Participation Status | R788 compound
Item
the patient has been treated previously treated with r788 under a different protocol.
boolean
C2348568 (UMLS CUI [1])
C2002836 (UMLS CUI [2])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial